<DOC>
	<DOC>NCT02719613</DOC>
	<brief_summary>The purpose of this study is to continue to provide elotuzumab and/or other study drugs to subjects who have participated on a prior protocol investigating elotuzumab who are not able to receive commercial drug supply.</brief_summary>
	<brief_title>Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Participated in a previous elotuzumab protocol (including, but not limited to HuLuc631703, CA204007, CA204009, or CA204011) and is deemed by the investigator to be deriving benefit from elotuzumab and/or other study drugs as defined by the previous protocol Receiving elotuzumab and/or other study drugs at the time of signature of informed consent Males and Females, ages 18 and older All subjects previously discontinued from an elotuzumab study for any reason Subjects not receiving clinical benefit from previous study therapy Subjects who are not medically well enough to receive study therapy as determined by the investigator Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>